Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies— a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2) - The Lancet

Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies— a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)  The Lancet